Metagenomi Therapeutics, Inc.
MGX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001785279
In the last 90 days, Metagenomi Therapeutics, Inc. insiders filed 1 open-market purchase and 3 sales; 43 institutions reported holding it in 13F filings for Q2 2026, worth $7.45M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $23.4K in total
- 1
- Insider sellsLast 90 days, $5.11K in total
- 3
- 13F holdersQ2 2026, −4 vs. previous quarter
- 43
- 13F valueReported value at the end of Q2 2026
- $7.45M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding MGX, Q2 2026
No superinvestor reported holding MGX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Metagenomi Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 (view filing)7:51 PM ET | Sep 9 | 2 days | Reid LaurenceDirector | PPurchase | +20.0K | $1.17 | +$23.4K | New position20.0K after | 2 lots |
| Sep 10, 2026 (view filing)3:47 PM ET | Sep 8 | 2 days | Wein MatthewSee Remarks | SSale | −358 | $1.16 | −$414.71 | −0.3%126.1K after | |
| Sep 10, 2026 (view filing)3:40 PM ET | Sep 8 | 2 days | Irish JianSee Remarks | SSale | −2.14K | $1.16 | −$2.48K | −0.6%375.4K after | |
| Sep 10, 2026 (view filing)3:34 PM ET | Sep 8 | 2 days | Wapnick PamelaChief Financial Officer | SSale | −1.91K | $1.16 | −$2.21K | −0.9%206.6K after | |
| Jun 10, 2026 (view filing) | Jun 5 | 5 daysLate | Wapnick PamelaChief Financial Officer | SSale | −2.88K | $1.30 | −$3.75K | −1.4%208.5K after | |
| Jun 10, 2026 (view filing) | Jun 5 | 5 daysLate | Irish JianSee Remarks | SSale | −3.74K | $1.30 | −$4.86K | −1.0%377.5K after | |
| Jun 10, 2026 (view filing) | Jun 5 | 5 daysLate | Wein MatthewSee Remarks | SSale | −558 | $1.30 | −$725.4 | −0.4%126.5K after | |
| Mar 9, 2026 (view filing) | Mar 5 | 4 days | Wapnick PamelaChief Financial Officer | SSale | −1.58K | $1.60 | −$2.53K | −0.8%187.4K after | |
| Mar 9, 2026 (view filing) | Mar 5 | 4 days | Wein MatthewSee Remarks | SSale | −482 | $1.60 | −$771.2 | −0.4%114.5K after | |
| Mar 9, 2026 (view filing) | Mar 5 | 4 days | Irish JianChief Executive Officer | SSale | −1.61K | $1.60 | −$2.57K | −0.5%333.8K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Metagenomi Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 1,077,700 | $1.28M | 0.00% | +19,756+1.9% | Added |
| Renaissance Technologies LLC | 742,400 | $883.5K | 0.00% | −45,500−5.8% | Reduced |
| Catalio Capital Management, LP | 528,993 | $629.5K | 0.12% | 00.0% | Unchanged |
| Peapod Lane Capital LLC | 525,024 | $624.8K | 0.42% | +8,263+1.6% | Added |
| Two Sigma Investments, LP | 513,701 | $611.3K | 0.00% | +16,934+3.4% | Added |
| Bridgeway Capital Management, LLC | 400,300 | $476.4K | 0.01% | +4,500+1.1% | Added |
| Wells Fargo & Company | 379,508 | $451.6K | 0.00% | +177,370+87.7% | Added |
| Geode Capital Management, LLC | 288,665 | $343.7K | 0.00% | −69,535−19.4% | Reduced |
| Pura Vida Investments, LLC | 264,391 | $314.6K | 0.85% | 00.0% | Unchanged |
| BlackRock, Inc. | 257,631 | $306.6K | 0.00% | +27,497+11.9% | Added |